Product Information
CEFDINIR 300 MG CAPSULE is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.4581 per EA under NDC 57237009960. Its NADAC has been published 603 times since Mar 18, 2015.
FDA first approved this application on Jan 7, 2008. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
57237009960
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CEFDINIRApproval Type
Generic (ANDA)
FDA Application
ANDA065434FDA Approved
1/7/2008
TE Code
AB
On Market Since
1/7/2008
Pharmacological Classes
Price Statistics
The NADAC for CEFDINIR 300 MG CAPSULE has been published 603 times since Mar 18, 2015, and over the history we have for it it has declined 65.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4581 per EA |
|---|---|
| All-time high | $1.3376 (Apr 15, 2015) |
| All-time low | $0.3507 (Nov 20, 2024) |
| 52-week high | $0.4752 |
| 52-week low | $0.4551 |
| Median price | $0.4901 |
| Average price | $0.5668 |
| Largest weekly change | +50.2% (Feb 22, 2017) |
| Weeks tracked | 603 |
| Tracking since | Mar 18, 2015 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Cefdinir market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cephalosporin Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CEFDINIR 300 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for CEFDINIR 300 MG CAPSULE, manufactured by Rising Pharma Holdings Inc., is $0.4581 per EA (NDC 57237009960), effective Sep 30, 2026.
How has the price of CEFDINIR 300 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for CEFDINIR 300 MG CAPSULE has declined 65.8%. It has been tracked across 603 weekly CMS publications since Mar 18, 2015.
What are the highest and lowest recorded NADAC prices for CEFDINIR 300 MG CAPSULE?
Since Mar 18, 2015, the NADAC for CEFDINIR 300 MG CAPSULE has ranged from a low of $0.3507 (Nov 20, 2024) to a high of $1.3376 (Apr 15, 2015), with a median of $0.4901 per EA.
Are there cheaper alternatives to CEFDINIR 300 MG CAPSULE?
7 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CEFDINIR 300 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures CEFDINIR 300 MG CAPSULE?
CEFDINIR 300 MG CAPSULE (NDC 57237009960) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.